1,Vertex continues to focus on the field of pain 2,Monte Rosa's CDK2 molecular glue degraders 3,Eisbach's ALC1 inhibitor 4,Roche's tri-complex inhibitors 5,Eli Lilly’s CRHR2 peptide agonists 6,LP(a) inhibitor from CSPC is better？
This report features four highly representative and innovative therapeutics recently profiled in the JMC Annotation column (submitted before December 2024 and with no clinical failure reported to date). The selection spans a diverse range of modalities, including covalent inhibitors, receptor-selective agonists, and CNS-penetrant compounds. The drugs are being developed by leading pharmaceutical and biotech companies such as Chiesi Farmaceutici S.p.A., Galapagos, Scorpion Therapeutics, and AstraZeneca.Through a systematic examination of the R&D paths of these compounds, this report aims to uncover their therapeutic potential, while also offering insight into their commercial prospects and developmental challenges.
This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of February, totaling 120 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.
